Atezolizumab is a PD-L1 inhibitor that is now standard first line therapy in combination with bevacizumab (atezo-bev) for patients with advanced HCC based on the IMbrave150 trial (Finn et al., 2020a). This evidence concerns the gene CD274 and hepatocellular carcinoma.